within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XH02_Romidepsin;
model Romidepsin 
   extends Pharmacolibrary.Drugs.ATC.L.L01XH02;

  annotation(Documentation(
    info ="<html><body><p>Romidepsin is a cyclic peptide histone deacetylase (HDAC) inhibitor used primarily for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). It is approved by regulatory agencies such as the FDA for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in adult patients with advanced cancers, administered intravenous infusion over 4 hours. Parameters derived from population PK modeling.</p><h4>References</h4><ol><li><p>Ro, T, et al., &amp; Ohtsu, T (2018). [Romidepsin (Istodax. <i>Nihon yakurigaku zasshi. Folia pharmacologica Japonica</i> 151(3) 122–129. DOI:<a href=&quot;https://doi.org/10.1254/fpj.151.122&quot;>10.1254/fpj.151.122</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29526921/&quot;>https://pubmed.ncbi.nlm.nih.gov/29526921</a></p></li><li><p>Kleinman, AJ, et al., &amp; Apetrei, C (2020). Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques. <i>Frontiers in immunology</i> 11 579158–None. DOI:<a href=&quot;https://doi.org/10.3389/fimmu.2020.579158&quot;>10.3389/fimmu.2020.579158</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33362765/&quot;>https://pubmed.ncbi.nlm.nih.gov/33362765</a></p></li><li><p>Iyer, SP, et al., &amp; Haverkos, BM (2024). Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study. <i>Haematologica</i> 109(1) 209–219. DOI:<a href=&quot;https://doi.org/10.3324/haematol.2022.281875&quot;>10.3324/haematol.2022.281875</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37439343/&quot;>https://pubmed.ncbi.nlm.nih.gov/37439343</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Romidepsin;
